Legato Capital Management LLC Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Key Points

• Legato Capital Management LLC reduced its holdings in Amicus Therapeutics by 74.7% in Q1, now owning 21,556 shares valued at $176,000.
• Amicus Therapeutics has received mixed ratings from analysts, with UBS raising its price target to $22.00, while Goldman Sachs decreased it to $9.00.
• The company has a market cap of $1.87 billion and its stock has fluctuated between a 12-month low of $5.51 and a high of $12.65.

Legato Capital Management LLC trimmed its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 74.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,556 shares of the biopharmaceutical company's stock after selling 63,583 shares during the quarter. Legato Capital Management LLC's holdings in Amicus Therapeutics were worth $176,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in FOLD. Virtus Fund Advisers LLC purchased a new position in Amicus Therapeutics in the fourth quarter valued at about $29,000. Covestor Ltd lifted its stake in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 2,312 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Amicus Therapeutics during the 4th quarter valued at approximately $59,000. GAMMA Investing LLC lifted its stake in shares of Amicus Therapeutics by 1,610.8% during the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 7,007 shares in the last quarter. Finally, Thrivent Financial for Lutherans purchased a new stake in shares of Amicus Therapeutics during the 4th quarter valued at approximately $104,000.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. UBS Group increased their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Finally, The Goldman Sachs Group lowered their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Trading Down 3.5%

Shares of FOLD stock traded down $0.22 on Friday, hitting $6.06. 3,505,161 shares of the company's stock traded hands, compared to its average volume of 4,104,743. The company has a debt-to-equity ratio of 2.02, a quick ratio of 2.47 and a current ratio of 3.34. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $12.65. The company's fifty day simple moving average is $6.08 and its 200 day simple moving average is $7.54. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -67.33 and a beta of 0.51.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.